Drug/Device Combination Product Guidance Should Be Expanded – NVCA
This article was originally published in The Gray Sheet
Executive Summary
The National Venture Capital Association urges FDA to provide better guidance for emerging drug/device combination product categories in comments addressing the agency's Critical Path initiative